Ayvakit (avapritinib) — United Healthcare
Myeloid/Lymphoid Neoplasms with eosinophilia
Initial criteria
- Diagnosis of myeloid/lymphoid neoplasms with eosinophilia
- Presence of a FIP1L1-PDGFRA rearrangement
- Presence of a PDGFRA D842V mutation
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Ayvakit therapy
Approval duration
12 months